Biopharmaceutical manufacturers continue to put quality at the forefront of their relationships.
Quality considerations have always been vital to biotherapeutic developers and CMOs. Yet, in 2016, it seems that these considerations are taking on a new emphasis. One of the main industry trends seen this year-increased attention to continuous bioprocessing-is at least partly driven by the potential for improved product quality.
Download the
BioPharm International 2016 Outsourcing Resources eBook.
FDA Approves Pfizer Combination Regimen for Treating R/R Diffuse Large B-Cell Lymphoma
February 14th 2025The approval of an ADCETRIS combination regimen is based on positive data from a Phase III trial where the combination regimen demonstrated a clinically meaningful reduction in the risk of death.